205 related articles for article (PubMed ID: 24475133)
1. Effect of BDNF Val66Met on memory decline and hippocampal atrophy in prodromal Alzheimer's disease: a preliminary study.
Lim YY; Villemagne VL; Laws SM; Ames D; Pietrzak RH; Ellis KA; Harrington K; Bourgeat P; Bush AI; Martins RN; Masters CL; Rowe CC; Maruff P;
PLoS One; 2014; 9(1):e86498. PubMed ID: 24475133
[TBL] [Abstract][Full Text] [Related]
2. BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease.
Lim YY; Villemagne VL; Laws SM; Ames D; Pietrzak RH; Ellis KA; Harrington KD; Bourgeat P; Salvado O; Darby D; Snyder PJ; Bush AI; Martins RN; Masters CL; Rowe CC; Nathan PJ; Maruff P;
Neurobiol Aging; 2013 Nov; 34(11):2457-64. PubMed ID: 23769397
[TBL] [Abstract][Full Text] [Related]
3. BDNF Val66Met in preclinical Alzheimer's disease is associated with short-term changes in episodic memory and hippocampal volume but not serum mBDNF.
Lim YY; Rainey-Smith S; Lim Y; Laws SM; Gupta V; Porter T; Bourgeat P; Ames D; Fowler C; Salvado O; Villemagne VL; Rowe CC; Masters CL; Zhou XF; Martins RN; Maruff P
Int Psychogeriatr; 2017 Nov; 29(11):1825-1834. PubMed ID: 28720165
[TBL] [Abstract][Full Text] [Related]
4. BDNF VAL66MET polymorphism and memory decline across the spectrum of Alzheimer's disease.
Lim YY; Laws SM; Perin S; Pietrzak RH; Fowler C; Masters CL; Maruff P;
Genes Brain Behav; 2021 Jun; 20(5):e12724. PubMed ID: 33369083
[TBL] [Abstract][Full Text] [Related]
5. Association of BDNF Val66Met With Tau Hyperphosphorylation and Cognition in Dominantly Inherited Alzheimer Disease.
Lim YY; Maruff P; Barthélemy NR; Goate A; Hassenstab J; Sato C; Fagan AM; Benzinger TLS; Xiong C; Cruchaga C; Levin J; Farlow MR; Graff-Radford NR; Laske C; Masters CL; Salloway S; Schofield PR; Morris JC; Bateman RJ; McDade E;
JAMA Neurol; 2022 Mar; 79(3):261-270. PubMed ID: 35099506
[TBL] [Abstract][Full Text] [Related]
6. APOE and BDNF polymorphisms moderate amyloid β-related cognitive decline in preclinical Alzheimer's disease.
Lim YY; Villemagne VL; Laws SM; Pietrzak RH; Snyder PJ; Ames D; Ellis KA; Harrington K; Rembach A; Martins RN; Rowe CC; Masters CL; Maruff P
Mol Psychiatry; 2015 Nov; 20(11):1322-8. PubMed ID: 25288138
[TBL] [Abstract][Full Text] [Related]
7. Lack of neural compensatory mechanisms of BDNF val66met met carriers and APOE E4 carriers in healthy aging, mild cognitive impairment, and Alzheimer's disease.
Gomar JJ; Conejero-Goldberg C; Huey ED; Davies P; Goldberg TE;
Neurobiol Aging; 2016 Mar; 39():165-73. PubMed ID: 26923413
[TBL] [Abstract][Full Text] [Related]
8. Impact of APOE and BDNF Val66Met Gene Polymorphisms on Cognitive Functions in Patients with Amnestic Mild Cognitive Impairment.
Cechova K; Andel R; Angelucci F; Chmatalova Z; Markova H; Laczó J; Vyhnalek M; Matoska V; Kaplan V; Nedelska Z; Ward DD; Hort J
J Alzheimers Dis; 2020; 73(1):247-257. PubMed ID: 31771052
[TBL] [Abstract][Full Text] [Related]
9. Interaction Between BDNF Val66Met and APOE4 on Biomarkers of Alzheimer's Disease and Cognitive Decline.
Stonnington CM; Velgos SN; Chen Y; Syed S; Huentelman M; Thiyyagura P; Lee W; Richholt R; Caselli RJ; Locke DEC; Lu B; Reiman EM; Su Y; Chen K
J Alzheimers Dis; 2020; 78(2):721-734. PubMed ID: 33044176
[TBL] [Abstract][Full Text] [Related]
10. BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease.
Lim YY; Hassenstab J; Cruchaga C; Goate A; Fagan AM; Benzinger TL; Maruff P; Snyder PJ; Masters CL; Allegri R; Chhatwal J; Farlow MR; Graff-Radford NR; Laske C; Levin J; McDade E; Ringman JM; Rossor M; Salloway S; Schofield PR; Holtzman DM; Morris JC; Bateman RJ;
Brain; 2016 Oct; 139(Pt 10):2766-2777. PubMed ID: 27521573
[TBL] [Abstract][Full Text] [Related]
11.
Boots EA; Schultz SA; Clark LR; Racine AM; Darst BF; Koscik RL; Carlsson CM; Gallagher CL; Hogan KJ; Bendlin BB; Asthana S; Sager MA; Hermann BP; Christian BT; Dubal DB; Engelman CD; Johnson SC; Okonkwo OC
Neurology; 2017 May; 88(22):2098-2106. PubMed ID: 28468845
[TBL] [Abstract][Full Text] [Related]
12. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
[TBL] [Abstract][Full Text] [Related]
13. DAT1 and BDNF polymorphisms interact to predict Aβ and tau pathology.
Ciampa CJ; Morin TM; Murphy A; Joie R; Landau SM; Berry AS;
Neurobiol Aging; 2024 Jan; 133():115-124. PubMed ID: 37948982
[TBL] [Abstract][Full Text] [Related]
14. Cross-sectional and longitudinal analysis of the relationship between Aβ deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease.
Doré V; Villemagne VL; Bourgeat P; Fripp J; Acosta O; Chetélat G; Zhou L; Martins R; Ellis KA; Masters CL; Ames D; Salvado O; Rowe CC
JAMA Neurol; 2013 Jul; 70(7):903-11. PubMed ID: 23712469
[TBL] [Abstract][Full Text] [Related]
15. The Influence of BDNF Val66Met Polymorphism on Cognition, Cerebrospinal Fluid, and Neuroimaging Markers in Non-Demented Elderly.
Xia H; Wang M; Li JQ; Tan CC; Cao XP; Tan L; Yu JT;
J Alzheimers Dis; 2019; 68(1):405-414. PubMed ID: 30775992
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of hippocampal volume and serum brain-derived neurotrophic factor as potential diagnostic markers of conversion from amnestic mild cognitive impairment to Alzheimer disease: A STROBE-compliant article.
Fang Y; Du N; Xing L; Duo Y; Zheng L
Medicine (Baltimore); 2019 Jul; 98(30):e16604. PubMed ID: 31348306
[TBL] [Abstract][Full Text] [Related]
17. Effect of APOE Genotype on Amyloid Deposition, Brain Volume, and Memory in Cognitively Normal Older Individuals.
Lim YY; Williamson R; Laws SM; Villemagne VL; Bourgeat P; Fowler C; Rainey-Smith S; Salvado O; Martins RN; Rowe CC; Masters CL; Maruff P;
J Alzheimers Dis; 2017; 58(4):1293-1302. PubMed ID: 28550258
[TBL] [Abstract][Full Text] [Related]
18. Relationships between performance on the Cogstate Brief Battery, neurodegeneration, and Aβ accumulation in cognitively normal older adults and adults with MCI.
Lim YY; Pietrzak RH; Bourgeat P; Ames D; Ellis KA; Rembach A; Harrington K; Salvado O; Martins RN; Snyder PJ; Masters CL; Rowe CC; Villemagne VL; Maruff P
Arch Clin Neuropsychol; 2015 Feb; 30(1):49-58. PubMed ID: 25467942
[TBL] [Abstract][Full Text] [Related]
19. Association study of the decreased serum BDNF concentrations in amnestic mild cognitive impairment and the Val66Met polymorphism in Chinese Han.
Yu H; Zhang Z; Shi Y; Bai F; Xie C; Qian Y; Yuan Y; Deng L
J Clin Psychiatry; 2008 Jul; 69(7):1104-11. PubMed ID: 18505307
[TBL] [Abstract][Full Text] [Related]
20. The implication of BDNF Val66Met polymorphism in progression from subjective cognitive decline to mild cognitive impairment and Alzheimer's disease: a 9-year follow-up study.
Bessi V; Mazzeo S; Bagnoli S; Padiglioni S; Carraro M; Piaceri I; Bracco L; Sorbi S; Nacmias B
Eur Arch Psychiatry Clin Neurosci; 2020 Jun; 270(4):471-482. PubMed ID: 31560105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
